ArticleFrontiers in immunology2023

Corrigendum: Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation.

Guo-Qing Tang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.